AXIOS September 24, 2024
The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss drugs in the U.S. during a congressional testimony on Tuesday.
Why it matters: Lars Fruergaard Jørgensen, who leads drug manufacturer Novo Nordisk, passed along accountability for access to these medications while being questioned about his company’s role in setting prices.
- “We don’t decide the price for patients. That is set by the insurance companies,” Jørgensen said.
Context: Sen. Bernie Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor and Pensions (HELP), last week outlined concerns that the high costs of these drugs could bankrupt Medicare and increase insurance premiums to unaffordable rates.
- “All we are...
Today's Sponsors
Today's Sponsor